BioSante Pharmaceuticals to Present at the Oppenheimer Health Care Conference

LINCOLNSHIRE, Ill.--(Business Wire)--
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M.
Simes, its president and CEO, will present an overview of the company and its
recently completed acquisition of Cell Genesys, as well as give a LibiGel®
(testosterone gel) update at the Oppenheimer 20th Annual Healthcare Conference
to be held on November 3-4, 2009 at the Waldorf-Astoria in New York City. Mr.
Simes will present on November 3, 2009 at 1:00 pm local time.

A live audio webcast of BioSante`s presentation at the conference may be
accessed at Oppenheimer Health Care Conference. A replay of the presentation
will be available at the same link.

About the Oppenheimer Health Care Conference

This Oppenheimer Annual Healthcare Conference will present a core group of
public and private companies who are leaders and pioneers in the pharmaceutical,
biotechnology, medical device, healthcare facility, health technology and
distribution, provider and service industries. Over 19 years, the Oppenheimer
Healthcare Conference has become a highly valuable investor conference in this
sector. Through formal company presentations and panels, attendees will gain
insight from, and access to, industry leaders. The companies participating in
this conference will address topical issues such as health reform, Medicare and
Medicaid, generic drug regulation, development of new blockbuster pharmaceutical
and biotechnology products, product safety and patent issues, cross-border
reimportation, Food and Drug Administration policy, managed care, and the
current M&A environment.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products
for female sexual health, menopause, contraception and male hypogonadism.
BioSante`s lead products include LibiGel (transdermal testosterone gel) in Phase
III clinical development by BioSante under a U.S. Food and Drug Administration
(FDA) SPA (Special Protocol Assessment) for the treatment of female sexual
dysfunction (FSD), and Elestrin (estradiol gel) developed through FDA approval
by BioSante, indicated for the treatment of moderate-to-severe vasomotor
symptoms associated with menopause, currently marketed in the U.S. Also in
development are Bio-T-Gel, a testosterone gel for male hypogonadism, and an oral
contraceptive in Phase II clinical development using BioSante patented
technology. The current market in the U.S. for estrogen and testosterone
products is approximately $2.5 billion and for oral contraceptives approximately
$3 billion. The company also is developing its calcium phosphate technology
(CaP) for aesthetic medicine (BioLook), as a vaccine adjuvant, including for an
H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek
opportunities for its GVAX cancer immunotherapies, which BioSante acquired from
Cell Genesys, Inc. and are non patient-specific therapies comprised of whole
tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage
colony-stimulating factor), an immune stimulatory cytokine, and then irradiated
for safety and are administered via intradermal injections on an outpatient
basis. Additional information is available online at: www.biosantepharma.com.

Alan Zachary,
McKinney/Chicago
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
For information about participating in the LibiGel clinical studies call or
visit the following:
877-BLOOM81; www.bloomstudy.com

Copyright Business Wire 2009